Kalvista Pharmaceuticals (NASDAQ: KALV) and Sonoma Pharmaceuticals (NASDAQ:SNOA) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, valuation, institutional ownership, risk, earnings, dividends and profitability.
This table compares Kalvista Pharmaceuticals and Sonoma Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Kalvista Pharmaceuticals has a beta of 2.52, indicating that its stock price is 152% more volatile than the S&P 500. Comparatively, Sonoma Pharmaceuticals has a beta of 1.24, indicating that its stock price is 24% more volatile than the S&P 500.
This is a summary of current ratings and recommmendations for Kalvista Pharmaceuticals and Sonoma Pharmaceuticals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Kalvista Pharmaceuticals presently has a consensus price target of $27.00, indicating a potential upside of 172.73%. Sonoma Pharmaceuticals has a consensus price target of $8.50, indicating a potential upside of 113.57%. Given Kalvista Pharmaceuticals’ stronger consensus rating and higher possible upside, equities research analysts plainly believe Kalvista Pharmaceuticals is more favorable than Sonoma Pharmaceuticals.
Valuation & Earnings
This table compares Kalvista Pharmaceuticals and Sonoma Pharmaceuticals’ revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Kalvista Pharmaceuticals||$1.50 million||71.15||-$18.60 million||N/A||N/A|
|Sonoma Pharmaceuticals||$12.82 million||1.47||$9.27 million||($2.79)||-1.43|
Sonoma Pharmaceuticals has higher revenue and earnings than Kalvista Pharmaceuticals.
Institutional & Insider Ownership
60.2% of Kalvista Pharmaceuticals shares are held by institutional investors. Comparatively, 13.2% of Sonoma Pharmaceuticals shares are held by institutional investors. 49.1% of Kalvista Pharmaceuticals shares are held by company insiders. Comparatively, 13.3% of Sonoma Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Kalvista Pharmaceuticals beats Sonoma Pharmaceuticals on 8 of the 12 factors compared between the two stocks.
Kalvista Pharmaceuticals Company Profile
KalVista Pharmaceuticals, Inc., formerly Carbylan Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The Company has developed a portfolio of small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME). The Company is developing a plasma kallikrein inhibitor, which is administered directly into the eye. The Company is engaged in advancing several product candidates developed from its portfolio into early clinical trials. The Company is progressing additional oral candidates towards regulatory preclinical studies. The Company’s HAE product candidate, KVD818, is an inhibitor of plasma kallikrein. The Company has initiated clinical testing of KVD818 in a Phase I clinical trial. It has completed an open-label single ascending dose Phase I trial in DME patients with KVD001.
Sonoma Pharmaceuticals Company Profile
Sonoma Pharmaceuticals, Inc., formerly Oculus Innovative Sciences, Inc., is a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care. The Company’s product portfolio consists of dermatology and advanced tissue care products based upon its technologies, such as Microcyn and Lipogrid. Microcyn is a small-molecule oxychlorine compound with antimicrobial and anti-inflammatory properties that, in clinical settings, reduces itch and pain associated with dermal irritations and wounds, such as sores, injuries and ulcers of dermal tissue. Lipogrid Technology contains selected lipids and a lipid precursor designed to penetrate the bilayers of the skin by blending with the natural lipid building blocks. Its products serve over five million patients across the globe by reducing infections, itch, pain, scarring and inflammatory responses. Its products are sold throughout the United States and internationally.
Receive News & Ratings for Kalvista Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kalvista Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.